Clinical and Humanistic Burden of IgA Nephropathy in Adult Patients
Kidney360 · 2025-01 · 6 (1) · 121-132
DOI: 10.34067/kid.0000000613 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, online erschienen am 22.10.2024. Verfasst von Sydney C W Tang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Adelphi Real World, Novartis, Adelphi Real World Novartis.
Abstract (Originalsprache)
Key Points IgA nephropathy (IgAN) exerts a significant humanistic burden on patients. Quality of life is impaired in patients with IgAN. Progression of disease in IgAN, especially proteinuria and GFR loss, are associated with the burden of disease.
Background
IgA nephropathy (IgAN) is a chronic, progressive kidney disease in which proteinuria, reduced eGFR, pain, and fatigue are common. How symptoms interact and affect patient quality of life (QoL) in real-world practice is poorly studied. This study investigated how patient and physician symptom perceptions differ and how proteinuria and eGFR correlate with pain, fatigue, and QoL in adult patients with IgAN.
Methods
Data were drawn from the Adelphi IgAN Disease Specific Program, a cross-sectional survey of physicians and their biopsy confirmed patients with IgAN in China, France, Germany, Italy, Spain, the United Kingdom, the United States, and Japan from June to October 2021. Physicians provided demographics and clinical characteristics, including pain and fatigue severity. The same patients completed a self-completion form containing questions on symptom severity, the EQ-5D-5L, Kidney Disease QoL, and Work Productivity and Activity Impairment questionnaires. Symptom scores were grouped by severity, and patients were grouped by proteinuria and eGFR. Analysis of variance, chi-squared, or Fisher exact tests were performed as appropriate and Dunn multiple comparisons with Bonferroni adjustment for pair-wise comparisons.
Results
Overall, 1515 patients were included (mean [SD] age: 43 [15] years, 60% [ n =903] male, 70% [ n =1020/1459] diagnosed >1 year ago). Pain was reported by 46% ( n =374) of physicians and 47% ( n =384) of patients and fatigue by 65% ( n =530) of physicians and 76% ( n =620) of patients. Both pain and fatigue increased with increased proteinuria and reduced eGFR (all P < 0.001). Finally, patients with increased proteinuria and reduced eGFR experienced worse ( P < 0.05) QoL and work productivity across all measures (except work absenteeism).
Conclusions
Patients with higher proteinuria and lower eGFR face higher symptom burden and reduced QoL compared to their counterparts. Physicians underestimated fatigue levels faced by patients. To improve QoL, more effective treatments are needed to prevent high proteinuria and preserve eGFR.
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.
- Novartis AG, Basel, Switzerland.
- Novartis Healthcare Pvt Ltd, Hyderabad, India.
- San Giovanni Bosco Hub Hospital (ERK-Net Member), University of Turin, Turin, Italy.
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
ORCID-Profile: Sydney C W Tang, Wei Chen, Aneesh Thomas George, Gisela Rovira Tomas, Raymond Przybysz, Serge Smeets, Keisha Golden, Jade Garratt-Wheeldon, Jonathan de Courcy, Richard Lafayette
Förderung
- Adelphi Real World, Novartis
- Adelphi Real World Novartis
Zitieren
APA
Tang, S. C. W., Chen, W., Aldworth, C., Thomas George, A., Kattlun, J., Rovira Tomas, G., Kroes, M., Roccatello, D., Przybysz, R., Smeets, S., Golden, K., Garratt-Wheeldon, J., Chatterton, E., de Courcy, J., & Lafayette, R. (2025). Clinical and Humanistic Burden of IgA Nephropathy in Adult Patients. Kidney360, 6(1), 121-132. https://doi.org/10.34067/kid.0000000613
Vancouver
Tang SCW, Chen W, Aldworth C, Thomas George A, Kattlun J, Rovira Tomas G, et al. Clinical and Humanistic Burden of IgA Nephropathy in Adult Patients. Kidney360. 2025;6(1):121-132. doi:10.34067/kid.0000000613
BibTeX
@article{Tang2025,
author = {Tang, Sydney C W and Chen, Wei and Aldworth, Carolina and Thomas George, Aneesh and Kattlun, Julia and Rovira Tomas, Gisela and Kroes, Michel and Roccatello, Dario and Przybysz, Raymond and Smeets, Serge and Golden, Keisha and Garratt-Wheeldon, Jade and Chatterton, Emma and de Courcy, Jonathan and Lafayette, Richard},
title = {Clinical and Humanistic Burden of IgA Nephropathy in Adult Patients},
journal = {Kidney360},
year = {2025},
volume = {6},
number = {1},
pages = {121--132},
doi = {10.34067/kid.0000000613}
}
EUVIMED